Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors

Cheng, Yuejuan; Meng, Changting; Ying, Hongyan; Zhou, Jianfeng; Yan, Xiaoyan; Gào, Xīn; Zhou, Na; Bai, Chunmei

doi:10.1097/md.0000000000012750

Cited by 8 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endostar is generally dosed at 7.5 mg/m 2 /day for 14 consecutive days (13,16). However, clinical trials have evaluated different doses, including 15 mg/day for 14 days or 45 mg/day on days 1, 3, and 4 (35,36). In the present study, a treatment regimen of 15 mg daily for 7 days was evaluated.…”

Section: Discussionmentioning

confidence: 99%

Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review

Tang

et al. 2023

Mol Clin Oncol

View full text Add to dashboard Cite

Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN.However, clinical trials are required to confirm the results of the present study.

show abstract

Section: Discussionmentioning

confidence: 99%

Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review

Tang

et al. 2023

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…A real-world study of 88 patients with sensitizing mutation negative NSCLC showed that Endostar combined with platinum-based doublet chemotherapy improved survival, but at the cost of higher occurrence of AEs [20]. A real-world study of 14 patients with pancreatic neuroendocrine tumors showed that the most common grade 1-2 AEs were neutropenia (43%) and leucopenia (21%) [21]. A real-world study of 23 patients with advanced mucosal melanoma showed that the most common severe AEs of Endostar with chemotherapy were leucopenia (13%), thrombocytopenia (13%), anemia (4%), nausea and vomiting (4%), and elevated transaminase (4%) [22].…”

Section: Discussionmentioning

confidence: 99%

Safety of Endostar in combination with chemotherapy in patients with cancer

wang

Zhu

Guo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: A number of studies indicated the benefits and safety of Endostar in combination with chemotherapy in cancer, but the exact real-life safety of Endostar is poorly known. This study aimed to assess the safety of Endostar in combination with chemotherapy in patients with cancer in a real-life setting in China. Methods: This was a retrospective study of patients treated with Endostarin combination with chemotherapy in the Chinese PLA General Hospital (Beijing, China) from 1 st January 2006to 31 st December 2017. All data were obtained from the Hospital Information System(HIS). Laboratory abnormalities were evaluated according to Common Terminology Criteria for Adverse Events(CTCAE) 4.0.Bleeding events and wound healing complications after surgery associated with Endostar were evaluated based on case records. Results: A total of 825 patients were included. There were no patients used Endostar alone in real-life settings. Overall, anemia occurred in 74.5% of the assessed patients, thrombocytopenia occurred in 29.0%, abnormal white blood cell count occurred in 54.5%, abnormal liver function occurred in 13.8%, and increased creatinine occurred in 1.2%. No definite bleeding events and wound healing complications after surgery associated with Endostar were found based on case records. Most laboratory AEs were of grade 1-2. Lung cancer, osteosarcoma and doxorubicin-based chemotherapy was associated with an increased risk of grade≥3 abnormal white blood cell count ( P <0.05). The total dose of Endostar was not associated with severe AEs(grade≥3)of thrombocytopenia and abnormal white blood cell count. Conclusion: The occurrence of AEs during treatment with Endostar in combination with chemotherapy differed across different tumor types and chemotherapy regimens. No new unexpected AEs relating to Endostar were observed from this study. The total dose of Endostar was not associated with increased risk of severe AEs (grade≥3)of thrombocytopenia and abnormal white blood cell count when used in combination with chemotherapy in the real-life setting.

show abstract

“…Gastric cancer patients with subsequent liver metastasis are extensively studied, and several phase II clinical trials are using recombinant endostatin (either alone or combined with other drugs) as an anti-tumour agent [ 221 , 222 , 223 ]. In addition, the effect of endostatin in advanced well-differentiated pancreatic neuroendocrine tumours is being tested [ 224 ].…”

Section: Heparan Sulfate Clinical Applications–recent Advancesmentioning

confidence: 99%

Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management

et al. 2021

View full text Add to dashboard Cite

In an era when cancer glycobiology research is exponentially growing, we are witnessing a progressive translation of the major scientific findings to the clinical practice with the overarching aim of improving cancer patients’ management. Many mechanistic cell biology studies have demonstrated that heparan sulfate (HS) glycosaminoglycans are key molecules responsible for several molecular and biochemical processes, impacting extracellular matrix properties and cellular functions. HS can interact with a myriad of different ligands, and therefore, hold a pleiotropic role in regulating the activity of important cellular receptors and downstream signalling pathways. The aberrant expression of HS glycan chains in tumours determines main malignant features, such as cancer cell proliferation, angiogenesis, invasion and metastasis. In this review, we devote particular attention to HS biological activities, its expression profile and modulation in cancer. Moreover, we highlight HS clinical potential to improve both diagnosis and prognosis of cancer, either as HS-based biomarkers or as therapeutic targets.

show abstract

Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors

Cited by 8 publications

References 34 publications

Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review

Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review

Safety of Endostar in combination with chemotherapy in patients with cancer

Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management

Contact Info

Product

Resources

About